logo-loader

Cardiol Therapeutics CEO discusses its clinical studies aimed at heart disease and the coronavirus

Published: 14:55 21 Apr 2021 EDT

Cardiol Therapeutics Inc (TSE:CRDL) (OTCQX:CRTPF) CEO David Elsley talks to Proactive about the Oakville, Ontario-based group's clinical studies aimed at treating inflammatory heart disease. Elsley says its recently completed Phase 1 study with CardiolRx supports its Phase II/III COVID-19 trial in patients with prior history of, or risk factors for, cardiovascular disease and the filing of its IND application with the FDA for an international Phase II trial in acute myocarditis.

Cardiol Therapeutics Receives FDA Orphan Drug Designation for Pericarditis...

Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) CEO David Elsley joined Steve Darling from Proactive to share some significant news: the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for the company's lead small molecule drug candidate aimed at treating...

on 15/2/24